Mondobiotech

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 17:15, 26 September 2019 (→‎History: Task 16: replaced (1×) / removed (0×) deprecated |dead-url= and |deadurl= with |url-status=;). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.


Mondobiotech is a Swiss-based biotechnology company focused on developing human peptides as medicaments for patients affected by rare diseases.

History

Mondobiotech was founded in 2000 by Fabio Cavalli and Dorian Bevec.[1] In March 2012, Pharma Times'in exclusive negotiations with Pierrel Research, the contact research division of the Italian company Pierrel.[2]

Research and development

Mondobiotech creates drugs for rare diseases.

Achievements

  • Winner of the Swiss Life Sciences Prize 2005.
  • Selected Technology Pioneer 2008 by The World Economic Forum.

Notes and references

  1. ^ "Archived copy". Archived from the original on 2012-07-20. Retrieved 2012-02-29.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ^ Mansell, Peter (6 March 2012). "Pierrel in negotiations for mondoBIOTECH merger". Pharma Times. Retrieved 9 March 2015.

See also

External links